Over the last years BIOMUNEX has raised dilutive and non-dilutive funding from different grants, tax credits, investments and pharmaceutical collaboration revenues.

BIOMUNEX raised equity capital from several private investors for several funding rounds.

Together with equity funding from investors, as an R&D focused company, BIOMUNEX has also received several grants, subsidies and French tax credit (Crédit d’Impôt de Recherche) since its inception, that enabled the company to develop the BiXAb® technology and the pipeline. Notably, BIOMUNEX received grants from BPI France and the French Research Ministry (i.e. I-Lab competition, ANR [Agence Nationale de la Recherche]) for several research programs.

The business model of BIOMUNEX is focused on two main axes that enable a consistent revenue stream:

  • BIOMUNEX establishes collaborations and out-licensing deals with pharmaceutical and biotech industry based on its BiXAb® technology. For instance, through a licensing deal signed with Sanofi in 2019 for the development of bi- and multi-specific antibodies, BIOMUNEX received a significant upfront payment; BIOMUNEX is also eligible to receive further clinical, regulatory and commercial milestone payments in the future.
  • BIOMUNEX’ objective is to partner and out-license its pipeline products ideally from clinical development and receive high-level upfronts, milestones, and royalties, enabling the further development of the pipeline and innovative technology at the company. In 2021 BIOMUNEX and Onward Therapeutics, a development stage oncology company, have entered in exclusive worldwide license and co-development agreement for one of BIOMUNEX proprietary bispecific antibody products in immuno-oncology. In addition, Onward Therapeutics made a strategic investment in BIOMUNEX.

In case of interest, interested parties are welcome to contact BIOMUNEX to explore possible drug discovery and development relationship as well as licensing or investment potential.